The UK NHS is to be advised that it shouldn't routinely provide pertuzumab (Perjeta) as a treatment for certain patients with advanced breast cancer. Draft guidance by NICE does not recommend its use because clinical trial data could not predict how long pertuzumab might extend people's lives for yet it costs much more than current NHS treatments.  For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/ViewsSoughtOnDraftNICEGuidanceThatSaysBreastCancerDrug...